08.07.2024
Publications category: PBPK-QSP
25.06.2024
Physiologically based pharmacokinetic modelling to support design of microarray patches delivering antiretroviral drugs to HIV positive children.
25.06.2024
Absorption, Bioavailability, and Immunogenicity after Subcutaneous Administration: Evaluation of a Subcutaneous Platform within the Open Systems Pharmacology framework
25.06.2024
A Physiologically Based Pharmacokinetic Model of Atorvastatin Acid Predicting CYP3A4 and OATP1B Drug–Drug Interactions
25.06.2024
Physiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation.
25.06.2024
Development of a PBPK model to predict monoclonal antibody pharmacokinetics and bioavailability following subcutaneous administration
26.03.2024
Bioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteers
01.11.2023
A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology framework
01.11.2023
Physiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive children
06.10.2023
Use of quantitative systems pharmacology pipelines to bridge in vitro and in vivo results in drug discovery
23.08.2023